In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arisaph Pharmaceuticals, Inc.

Latest From Arisaph Pharmaceuticals, Inc.

Cardio And Metabolic Deals, Launches Falter – Will Innovation Help?

Despite the high unmet medical need in the cardiovascular and metabolic indications, companies are increasingly reluctant to make deals in the sector. But unique therapeutic approaches to diseases could bring new life.

BioPharmaceutical North America

After Statins, What Next?

As statins go generic, a host of companies are hunting out new treatments for cholesterol control. They're not put off by recent setbacks, given the huge remaining unmet need and commercial opportunity. Many new companies are still trying to lower LDL and/or raise HDL, but anti-inflammatory approaches are increasingly popular too, as scientists better understand the nature and process of plaque formation.

BioPharmaceutical Business Strategies

Borean Pharma AS

Borean aims to leverage the trimeric properties of one human protein, tetranectin, to develop second-generation protein therapeutics to treat autoimmune disease and cancer. Its first candidate is a TNF-alpha antagonist in preclinical testing for autoimmune diseases, but the company also has ongoing early work on several undisclosed oncology targets.


Kos/Biovail: How a Mid-Cap Can Win in Primary Care

In May 2005 Kos Pharmaceuticals took over three of Biovail Corp's hypertension drugs plus most of its associated sales force, paying just 1.4 times 2004 sales-or roughly a fifth of what Biovail had paid for the same products less than five years ago. The deal draws attention to why the two mid-cap companies--similarly sized, and, until recently, with a similar business model--have fared so differently in primary care.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • Triad Pharmaceuticals, Inc.